He Y - Search Results

1

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction adenocarcinoma: perspectives from the United States and China.

Lang W, Ai Q, Zhang W, Jiang Q, He Y, Ouyang M. Lang W, et al. Among authors: he y. Front Pharmacol. 2024 Nov 20;15:1461571. doi: 10.3389/fphar.2024.1461571. eCollection 2024. Front Pharmacol. 2024. PMID: 39635432 Free PMC article.

2

Cost-effectiveness analysis of nivolumab versus placebo for relapsed malignant mesothelioma.

Lang W, Wei J, Jiang Q, Ai Q, Zhao X, Xiao L, He Y. Lang W, et al. Among authors: he y. Int J Clin Pharm. 2024 Feb;46(1):158-165. doi: 10.1007/s11096-023-01662-1. Epub 2023 Nov 22. Int J Clin Pharm. 2024. PMID: 37991664 Clinical Trial.

3

Cost-effectiveness analysis of tislelizumab plus chemotherapy versus standard chemotherapy in first-line treatment for extensive-stage small cell lung cancer: perspectives from the United States and China.

Lang W, Ai Q, He Y, Pan Y, Jiang Q, Ouyang M, Sun T. Lang W, et al. Among authors: he y. Int J Clin Pharm. 2024 Dec;46(6):1536-1545. doi: 10.1007/s11096-024-01802-1. Epub 2024 Sep 14. Int J Clin Pharm. 2024. PMID: 39276261

4

Global trends and research hotspots in perioperative management of lung cancer: a bibliometric analysis from 2004 to 2024.

Jiang Q, Wei Z, Liu P, Li Z, Jiang H, Cao Y, Zhang B, Yan Y, He Y. Jiang Q, et al. Among authors: he y. Front Immunol. 2024 Nov 21;15:1500686. doi: 10.3389/fimmu.2024.1500686. eCollection 2024. Front Immunol. 2024. PMID: 39640262 Free PMC article.

5

Prognostic implications of synaptophysin, CD56, thyroid transcription factor-1, and Ki-67 in pulmonary high-grade neuroendocrine carcinomas.

He Y, Zhao L, Tang X, Jiang Q, Zhao X, Cao Y. He Y, et al. Ann Diagn Pathol. 2024 Feb;68:152239. doi: 10.1016/j.anndiagpath.2023.152239. Epub 2023 Nov 22. Ann Diagn Pathol. 2024. PMID: 38006863 Free article.

6

Zhang X, Li J, Yao Y, Zhou M, He Y, Zhao Y. Zhang X, et al. Among authors: he y. J Gastroenterol. 2025 Jan 12. doi: 10.1007/s00535-025-02212-4. Online ahead of print. J Gastroenterol. 2025. PMID: 39799524

7

AXL: shapers of tumor progression and immunosuppressive microenvironments.

Liu Y, Xu L, Dou Y, He Y. Liu Y, et al. Among authors: he y. Mol Cancer. 2025 Jan 11;24(1):11. doi: 10.1186/s12943-024-02210-9. Mol Cancer. 2025. PMID: 39799359 Review.

8

CF₂H-synthon enables asymmetric radical difluoroalkylation for synthesis of chiral difluoromethylated amines.

Liu P, He Y, Jiang CH, Ren WR, Jin RX, Zhang T, Chen WX, Nie X, Wang XS. Liu P, et al. Among authors: he y. Nat Commun. 2025 Jan 11;16(1):599. doi: 10.1038/s41467-025-55912-z. Nat Commun. 2025. PMID: 39799146

9

Clear cell borderline ovarian tumor: A retrospective study and literature review.

Liu Y, Wang D, Jia C, Su N, Zhang J, He Y, Yang J, Xiang Y. Liu Y, et al. Among authors: he y. Eur J Obstet Gynecol Reprod Biol. 2025 Jan 10;306:75-80. doi: 10.1016/j.ejogrb.2025.01.012. Online ahead of print. Eur J Obstet Gynecol Reprod Biol. 2025. PMID: 39798493

10

mTOR/HIF-1α pathway-mediated glucose reprogramming and macrophage polarization by Sini decoction plus ginseng soup in ALF.

Zhang J, Hao L, Li S, He Y, Zhang Y, Li N, Hu X. Zhang J, et al. Among authors: he y. Phytomedicine. 2025 Jan 5;137:156374. doi: 10.1016/j.phymed.2025.156374. Online ahead of print. Phytomedicine. 2025. PMID: 39798342

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

40,746 results

Search Page

Filters